Arvinas, Inc. has grown revenue 26% a year over three years and 66% a year over five. Revenue growth, 3-year annual rate: +26% (Biotechnology median +17%). Revenue growth, 5-year rate: +66%, growth has slowed since the five-year average. Years of annual history on file: 9, FY2017 to FY2025, as filed.

ARVNArvinas, Inc.

Healthcare

$7.52-19% 1Y

$7.52

$6.9852 weeks$13.83

Is it growing?

Watch

Growth is fading: revenue shrinking (−15% year on year), earnings down −124% year on year, and operating margin narrowing (−198.6 points).

3 to watch

Revenue trend−15% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +66% a year.

Earnings trend−124% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−198.6 points operating

Trailing-twelve-month operating margin, -308.3% now against -109.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ARVN growing?

Arvinas, Inc. has grown revenue 26% a year over three years and 66% a year over five.

+26%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +66%
Revenue growth, 5-year rate · +26% over three · growth has slowed since the five-year average
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›